Holen Sie sich die Stockscreener-App
4.71
2.89%
-0.14
Handel nachbörslich:
4.73
0.02
+0.42%
Schlusskurs vom Vortag:
$4.85
Offen:
$4.88
24-Stunden-Volumen:
532.59K
Relative Volume:
0.38
Marktkapitalisierung:
$169.64M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-35.17M
KGV:
-4.0453
EPS:
-1.1643
Netto-Cashflow:
$-29.83M
1W Leistung:
+3.52%
1M Leistung:
+8.53%
6M Leistung:
+344.34%
1J Leistung:
+302.56%
1-Tages-Spanne:
$4.68
$5.07
1-Wochen-Bereich:
$4.44
$5.235
52-Wochen-Spanne:
$1.00
$6.9099
An 2 Therapeutics Inc Stock (ANTX) Company Profile
Firmenname
An 2 Therapeutics Inc
Sektor
Branche
Telefon
(650) 331-9090
Adresse
1300 EL CAMINO REAL, SUITE 100, MENLO PARK
Compare ANTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANTX
An 2 Therapeutics Inc
|
4.71 | 174.68M | 0 | -35.17M | -29.83M | -1.1643 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-09 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2024-08-09 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-07-03 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-04-02 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2024-02-13 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-02-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-12 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-02-12 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-01-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
Alle ansehen
An 2 Therapeutics Inc Aktie (ANTX) Neueste Nachrichten
This Summit Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Friday - Benzinga
Relay Therapeutics (Nasdaq: RLAY) shares early zovegalisib vascular anomaly data - Stock Titan
Amplexd Therapeutics Initiates Phase 2 Clinical Trial of Investigational EGCg-Based HPV Therapy - GlobeNewswire
Tenaya Therapeutics, Inc. (TNYA) Discusses RIDGE-1 Phase Ib/II Data on TN-401 Gene Therapy for PKP2-Associated ARVCSlideshow (NASDAQ:TNYA) 2026-05-17 - Seeking Alpha
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $26, Implies 2% Upside - TradingView
Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026 - PR Newswire
Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye DiseaseSlideshow (NASDAQ:VRDN) 2026-05-09 - Seeking Alpha
Millennium-linked entities file 13G/A for Tenax Therapeutics (NASDAQ: TENX) reporting ~2% stakes - Stock Titan
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease - Business Wire
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with - GlobeNewswire
Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON Study - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Advances Diabetes Drug Into Phase 2 Trial - Yahoo Finance
Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer - Investing News Network
Dianthus Therapeutics Inc (DNTH): FDA Makes Trials Easier - Yahoo Finance
Thryv Therapeutics Commences Patient Dosing in Wave II Clinical Study for Long QT Syndrome and Receives FDA Fast Track Designation for THRV-1268 - BioSpace
Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer - GlobeNewswire
Spotlighting Abeona Therapeutics And 2 More High Growth Stocks Insiders Favor - Yahoo Finance
Obsidian Therapeutics to Present OBX-115 Phase 2 Clinical Data in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting - Business Wire
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia - GlobeNewswire
Black Diamond Therapeutics Announces Oral Presentation of - GlobeNewswire
Analysts Adjust Cadrenal Therapeutics, Inc. (CVKD) Valuation After Including CAD-1005 Program - Yahoo Finance
ZEVRA THERAPEUTICS, INC. ($ZVRA) CEO 2025 Pay Revealed - Quiver Quantitative
YA II affiliates report 101,772 shares in TransCode Therapeutics (RNAZ) under convertible note - Stock Titan
MapLight Therapeutics: Strong Balance Sheet Ahead of Crucial Phase 2 Readouts in Q3 2026 - AlphaStreet
Allogene Therapeutics, Inc. Files Form 8-K Current Report with SEC on April 13, 2026 2 - Minichart
Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell LymphomaSlideshow (NASDAQ:ALLO) 2026-04-14 - Seeking Alpha
ALLO Stock Jumps As Pivotal ALPHA3 CAR-T Data Loom - StocksToTrade
After layoffs, biotech exits 2 Boston-area leases - NBC Boston
Spyre Therapeutics Reports Positive Phase 2 Data for SPY001 in Ulcerative Colitis Trial - Quiver Quantitative
Allogene Therapeutics to Announce Interim Futility Analysis - GlobeNewswire
AQUESTIVE THERAPEUTICS, INC. (AQST) DEADLINE ALERT - GlobeNewswire
INVESTOR ALERT: Soleno Therapeutics Inc. (SLNO) Investors - GlobeNewswire
Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14 - Yahoo Finance
Cognition Therapeutics, Inc. CEO Lisa Ricciardi to Present at 25th Annual Needham Virtual Healthcare Conference - Quiver Quantitative
OYE Therapeutics achieves first patient first dose in 505(b)(2) bridging study - Purdue Research Foundation
Oppenheimer Revises Soleno Therapeutics Price Target Amid Delayed US Launch - StocksToTrade
MiNK AACR study targets gastroesophageal cancer after PD-1 failure - Stock Titan
FDA grants Fast Track to Context Therapeutics (CNTX) CTIM-76 in platinum-resistant ovarian cancer - Stock Titan
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine - GlobeNewswire
Rapport Therapeutics to Present New Phase 2 Treatment - GlobeNewswire
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting - GlobeNewswire
United Therapeutics Soars as Clinical Trials Meet Key Endpoints - StocksToTrade
Plus Therapeutics, Inc. Announces 1-for-25 Reverse Stock Split Effective April 2, 2026 | PSTV Stock News - Quiver Quantitative
To keep its Nasdaq listing, Plus Therapeutics enacts 1-for-25 split - Stock Titan
AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease - Business Wire
Relmada Therapeutics: 2 New Assets, 2 New 'Blockbusters'? I'd Wait And See (NASDAQ:RLMD) - Seeking Alpha
Protara Therapeutics (TARA) sustains 68% CR in ADVANCED-2 and activates $5.25 warrants - Stock Titan
Structure Therapeutics Phase 2 Obesity Data Shifts Focus To Phase 3 - Yahoo Finance
Beam Therapeutics Inc. (BEAM) Discusses Topline Phase I/II Data for BEAM-302 in Alpha-1 Antitrypsin DeficiencySlideshow (NASDAQ:BEAM) 2026-03-27 - Seeking Alpha
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 - Finviz
Sarepta Therapeutics, Inc. (SRPT) Discusses Preliminary Phase I/II Data for SRP-1001 in FSHD1 and SRP-1003 in DM1Slideshow (NASDAQ:SRPT) 2026-03-25 - Seeking Alpha
Finanzdaten der An 2 Therapeutics Inc-Aktie (ANTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
An 2 Therapeutics Inc-Aktie (ANTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Day Lucy | Chief Financial Officer |
Jan 06 '26 |
Sale |
1.01 |
5,512 |
5,578 |
75,363 |
| Day Lucy | Chief Financial Officer |
Jan 05 '26 |
Sale |
1.00 |
3,295 |
3,305 |
80,875 |
| Prior Stephen David | Chief Strategy Officer |
Jan 05 '26 |
Sale |
1.00 |
3,604 |
3,615 |
61,944 |
| Prior Stephen David | Chief Strategy Officer |
Jan 06 '26 |
Sale |
1.01 |
2,858 |
2,892 |
59,086 |
| Chanda Sanjay | Chief Development Officer |
Jan 06 '26 |
Sale |
1.01 |
5,956 |
6,027 |
75,823 |
| Chanda Sanjay | Chief Development Officer |
Jan 05 '26 |
Sale |
1.00 |
3,295 |
3,305 |
81,779 |
| Eizen Joshua M | See Remarks |
Jan 05 '26 |
Sale |
1.00 |
17,923 |
17,948 |
159,430 |
| Eizen Joshua M | See Remarks |
Jan 06 '26 |
Sale |
1.01 |
6,931 |
7,014 |
152,499 |
| Eizen Joshua M | See Remarks |
Nov 04 '25 |
Sale |
1.14 |
2,819 |
3,214 |
177,353 |
| Prior Stephen David | Chief Strategy Officer |
Nov 04 '25 |
Sale |
1.14 |
765 |
872 |
65,548 |
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):